O Shaughnessy Asset Management LLC Reduces Position in Sanofi (NASDAQ:SNY)

O Shaughnessy Asset Management LLC lowered its holdings in Sanofi (NASDAQ:SNY) by 12.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 115,257 shares of the company’s stock after selling 16,977 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Sanofi were worth $5,559,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Synergy Asset Management LLC bought a new position in Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in Sanofi during the fourth quarter valued at approximately $31,000. Sunbelt Securities Inc. increased its holdings in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in Sanofi in the 4th quarter worth approximately $44,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 2.0 %

NASDAQ SNY opened at $54.34 on Wednesday. The stock’s 50-day simple moving average is $55.28 and its two-hundred day simple moving average is $52.73. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $137.91 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.